|
|||||
|
|
The microRNAs (miRs) overexpressing mesenchymal stem cells (MSCs) therapy in neurological disorders; hope or hype |
|
| Authors: | Sulieman Ibraheem Shelash Al-Hawary Anas Yahya Ali Yasser Fakri Mustafa Ria Margiana Shamsutdinova Maksuda Ilyasovna Montather F Ramadan Sami G Almalki Marim Alwave Safa Alkhayyat Ali Alsalamy |
| Institution: | 1. Department of Business Administration, Business School, Al al-Bayt University, Mafraq, Jordan
Contribution: Writing - original draft, Writing - review & editing;2. Department of Nursing, Al-maarif University College, Ramadi, Al-Anbar, Iraq Contribution: Investigation, Project administration, Writing - original draft, Writing - review & editing;3. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq Contribution: Investigation, Writing - original draft, Writing - review & editing;4. Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia;5. Tashkent Medical Academy, Tashkent, Uzbekistan Contribution: Writing - original draft, Writing - review & editing;6. College of Dentistry, Al-Ayen University, Thi-Qar, Iraq;7. Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah, Saudi Arabia;8. Medical Technical College, Al-Farahidi University, Baghdad, Iraq Contribution: Writing - original draft;9. College of Pharmacy, The Islamic University, Najaf, Iraq Contribution: Writing - original draft;10. College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, Iraq Contribution: Writing - original draft |
| Abstract: | Altered expression of multiple miRNAs was found to be extensively involved in the pathogenesis of different neurological disorders including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. One of the biggest concerns within gene-based therapy is the delivery of the therapeutic microRNAs to the intended place, which is obligated to surpass the biological barriers without undergoing degradation in the bloodstream or renal excretion. Hence, the delivery of modified and unmodified miRNA molecules using excellent vehicles is required. In this light, mesenchymal stem cells (MSCs) have attracted increasing attention. The MSCs can be genetically modified to express or overexpress a particular microRNA aimed with promote neurogenesis and neuroprotection. The current review has focused on the therapeutic capabilities of microRNAs-overexpressing MSCs to ameliorate functional deficits in neurological conditions. |
| Keywords: | gene therapy mesenchymal stem cell (MSC) miRNA neurogenesis neurological diseases |